Natixis Advisors LLC Buys 5,846 Shares of STERIS plc $STE

Natixis Advisors LLC lifted its stake in shares of STERIS plc (NYSE:STE) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 151,822 shares of the medical equipment provider’s stock after buying an additional 5,846 shares during the period. Natixis Advisors LLC’s holdings in STERIS were worth $37,567,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of STERIS by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider’s stock valued at $3,022,114,000 after acquiring an additional 50,393 shares in the last quarter. State Street Corp grew its position in STERIS by 2.4% during the 2nd quarter. State Street Corp now owns 4,188,103 shares of the medical equipment provider’s stock worth $1,006,069,000 after acquiring an additional 98,220 shares during the last quarter. Geode Capital Management LLC increased its holdings in STERIS by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider’s stock worth $592,980,000 after purchasing an additional 46,859 shares in the last quarter. Orbis Allan Gray Ltd increased its holdings in STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after purchasing an additional 556,088 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in STERIS by 16.4% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock valued at $387,797,000 after purchasing an additional 221,199 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $275.20.

STERIS Stock Performance

Shares of STERIS stock opened at $227.60 on Tuesday. The stock has a market cap of $22.32 billion, a price-to-earnings ratio of 31.74 and a beta of 1.05. STERIS plc has a twelve month low of $204.90 and a twelve month high of $269.44. The company’s fifty day moving average is $253.80 and its 200 day moving average is $251.42. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The business’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Sell-side analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is 35.15%.

Insider Activity

In related news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the transaction, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.07% of the stock is owned by company insiders.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.